SAN DIEGO, Feb. 4, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:
The 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 8:30 a.m. Eastern Time at the Waldorf=Astoria Hotel in New York City.
Leerink Swann Hot Topics in Therapeutics Roundtable Conference on Wednesday, February 16, 2011 at 2:40 p.m. Eastern Time at The Roosevelt Hotel in New York City.
Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of these presentations will be available at the same location for 30 days following the meeting.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance